Surmodics, Inc. (NASDAQ:SRDX) Files An 8-K Other Events

On August 12, 2019, Surmodics, Inc. (the “Company”) updated its investor presentation, which is available under the “Investors” section of the Company’s website at www.surmodics.com. Representatives of the Company will use the updated presentation in various meetings with analysts and investors from time to time. A copy of the presentation is attached to this report as Exhibit 99.1.

The information in this Item 8.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under Section 18, nor shall such information be deemed incorporated by reference into any filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

SURMODICS INC Exhibit
EX-99.1 2 a52077781ex99_1.htm EXHIBIT 99.1 Exhibit 99.1  Gary MaharajPresident and CEOTim ArensVice President of Finance and CFOAugust 2019  1     Safe Harbor  Some of the statements made during this presentation may be considered forward-looking statements. Statements that are not historical or current facts,…
To view the full exhibit click here

About Surmodics, Inc. (NASDAQ:SRDX)

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.